Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: February 2009
-
By Donald Zuhn — In December, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, issued its forecast for venture investment in the coming year, predicting that most sectors would see a continued slowdown in investment in 2009 (see "NVCA Predicts Another Slow Year for Venture-backed Businesses in…
-
By Donald Zuhn — Last week, the U.S. Patent and Trademark Office hosted a roundtable discussion on deferred examination. The roundtable, which lasted about four hours, brought together two dozen participants, representing a variety of industries and organizations (as well as positions on the issue), to discuss the advantages and disadvantages of implementing a…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Monsanto Co. et al. v. Schroeder et al.2:09-cv-10460; filed February 6, 2009 in the Eastern District of Michigan Infringement of U.S. Patent…
-
February 17-18, 2009 – Pharma/Biotech Patent Litigation (C5) – Amsterdam, Netherlands February 23-24, 2009 – Pharmaceutical and Biotech Patent Claim Drafting*** (American Conference Institute) – Palo Alto, CA February 25-26, 2009 – Optimizing Patent Strategies at Patent Forum 2009 (World Research Group) – San Francisco, CA March 2-3, 2009 – 3rd Annual Patent Law Institute…
-
By Jason Derry —Merck to Buy Biologics Division from Insmed Insmed Inc. and Merck have announced a deal in which Merck will purchase Insmed's research and production division and facility for developing follow-on biologics for $130 million (see Insmed press release). Merck will receive Insmed's follow-on biologics platform, and its development and production facility…
-
The American Bar Association (ABA) Section of Intellectual Property Law will be holding the 24th Annual Intellectual Property Law Conference on April 1-4, 2009 in Arlington, VA. Among the topics that will be covered at the conference are: • The Patent Reform Movement – Where Is It Going and Will It Get There?• From Drafting…
-
Practising Law Institute (PLI) will be holding its 3rd Annual Patent Law Institute on March 2-3, 2009 in New York, NY and on March 23-24, 2009 in San Francisco, CA. A live webcast of the New York session will also be available. The two-day conference consists of six one-hour plenary sessions of broad interest to…
-
C5 (UK) will be holding its 6th Annual Freedom to Operate Forum on April 20-21, 2009 in London, England. The conference will provide practical knowledge and strategic advice on: • Effective FTO landscaping, searching, and competitor analysis;• The latest EPO, U.S., and European national case law on claim interpretation and validity;• The impact of recent…
-
By Donald Zuhn — This morning, the U.S. Patent and Trademark Office hosted a roundtable discussion on deferred examination. The roundtable, which lasted about four hours, brought together two dozen participants, representing a variety of industries and organizations (as well as positions on the issue), to discuss the advantages and disadvantages of implementing a…
-
By Kevin E. Noonan — Rick Weiss gets it when it comes to the value of patents. "Patents assure an inventor a period of time, generally 20 years, to exclude others from using the invention, in return for a full explication of that invention by the patent holder," he says. "The assurance that competitors…
Patent Docs 